Financial Performance - Operating revenue for Q3 2023 reached RMB 18,214,219 thousand, an increase of 3.58% year-on-year[2] - Net profit attributable to shareholders was RMB 980,002 thousand, reflecting a growth of 10.81% compared to the same period last year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 840,145 thousand, with a slight increase of 0.78% year-on-year[2] - The basic earnings per share for Q3 2023 was RMB 0.603, up by 10.81% year-on-year[2] - Total operating revenue for the first three quarters of 2023 reached RMB 58.18 billion, an increase of 6.3% compared to RMB 54.81 billion in the same period of 2022[14] - Operating profit for the first three quarters of 2023 was RMB 4.76 billion, up from RMB 4.46 billion in the same period of 2022, reflecting a growth of 6.6%[15] - Net profit attributable to shareholders of the parent company for the first three quarters of 2023 was RMB 3.79 billion, compared to RMB 3.47 billion in 2022, representing an increase of 9.3%[15] - Basic and diluted earnings per share for the first three quarters of 2023 were both RMB 2.332, up from RMB 2.137 in the same period of 2022[16] - The total comprehensive income attributable to shareholders of the parent company for the first three quarters of 2023 was RMB 3.79 billion, compared to RMB 3.48 billion in 2022, an increase of 8.5%[16] Assets and Liabilities - Total assets at the end of the reporting period amounted to RMB 74,353,331 thousand, a decrease of 0.42% from the end of the previous year[2] - Total assets increased to RMB 74.35 billion in 2023 from RMB 74.67 billion in 2022, indicating a slight decrease of 0.4%[13] - Total liabilities decreased to RMB 37,977,384,691.70 from RMB 41,027,440,697.52, a reduction of 7.5%[11] - The company’s total liabilities and equity amounted to RMB 36.38 billion in 2023, up from RMB 33.64 billion in 2022, reflecting an increase of 8.2%[13] Shareholder Information - Shareholders' equity attributable to the parent company increased to RMB 34,660,070 thousand, representing an increase of 8.09% year-on-year[2] - The company had a total of 91,342 common shareholders at the end of the reporting period[4] - The largest shareholder, Guangzhou Pharmaceutical Group Co., Ltd., holds 45.04% of the shares[5] - The company reported a total of 732,305,103 shares held by Guangzhou Pharmaceutical Group Co., Ltd., the largest shareholder[6] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was RMB 901,626 thousand, showing a significant decrease of 72.67% year-on-year[4] - Operating cash inflow for the first three quarters of 2023 was RMB 53.47 billion, a slight increase from RMB 52.59 billion in the same period of 2022, representing a growth of 1.68%[17] - Cash outflow from operating activities totaled RMB 52.57 billion in 2023, compared to RMB 49.29 billion in 2022, indicating an increase of 6.56%[18] - Net cash flow from operating activities decreased to RMB 901.63 million in 2023, down 72.66% from RMB 3.30 billion in 2022[18] - Cash inflow from investment activities was RMB 2.36 billion in 2023, significantly higher than RMB 253.22 million in 2022[18] - Net cash flow from investment activities was negative at RMB 2.21 billion in 2023, an improvement from a loss of RMB 5.87 billion in 2022[18] - Cash inflow from financing activities was RMB 10.80 billion in 2023, slightly lower than RMB 11.38 billion in 2022, a decrease of 5.06%[19] - Net cash flow from financing activities turned negative at RMB 916.78 million in 2023, compared to a positive flow of RMB 1.29 billion in 2022[19] - The ending cash and cash equivalents balance as of September 2023 was RMB 18.59 billion, down from RMB 19.73 billion at the end of September 2022, a decrease of 5.78%[19] Current Assets and Receivables - As of September 30, 2023, total current assets amounted to RMB 52,924,980,357.93, a decrease of 7.5% from RMB 57,064,311,513.29 on December 31, 2022[8] - Cash and cash equivalents decreased to RMB 19,873,967,228.77 from RMB 22,499,552,770.75, representing a decline of 11.5%[8] - Accounts receivable increased to RMB 16,521,846,517.80, up 11.2% from RMB 14,857,591,768.49[8] - Total non-current assets reached RMB 21,428,350,404.03, an increase of 21.5% compared to RMB 17,600,987,263.45 at the end of 2022[9] - The total amount of accounts payable rose to RMB 12,620,557,642.25, an increase of 12.7% from RMB 11,200,347,828.21[10] Research and Development - Research and development expenses for the first three quarters of 2023 were RMB 579.48 million, down from RMB 664.39 million in 2022, a decrease of 12.8%[14] - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[7] Foreign Currency Impact - The company recorded a net foreign currency translation difference of RMB 5.07 million in the first three quarters of 2023, compared to RMB 17.80 million in 2022, indicating a decrease of 71.5%[16] - The impact of exchange rate changes on cash and cash equivalents was positive at RMB 6.75 million in 2023, compared to a negative impact of RMB 876.30 thousand in 2022[19]
白云山(00874) - 2023 Q3 - 季度业绩